{"id":418585,"date":"2021-01-21T08:08:09","date_gmt":"2021-01-21T13:08:09","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=418585"},"modified":"2021-01-21T08:08:09","modified_gmt":"2021-01-21T13:08:09","slug":"salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\/","title":{"rendered":"Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">HOUSTON, Jan.  21, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zXrsPovEu2_D_7zjTIWevK7F3EZ_IoAyo2DCwOOpZOgAXcTdRHBD0A_A2otY-8ZaabiazIMkesdUbJn-O1qZ1l4rVr93hn79K_5uRZJnJg75LiVQuFj9CAsh17c-FCm8\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Salarius Pharmaceuticals, Inc<\/a>. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that it has received a letter from the Nasdaq Listing Qualifications staff notifying the Company that it has regained compliance with Nasdaq&#8217;s Listing Rule 5550(a)(2) pertaining to the minimum bid price requirement for continued listing on the Nasdaq Capital Market.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Salarius Pharmaceuticals<\/strong><br \/>\n        <br \/>Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius\u2019 lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options. Seclidemstat is currently in a Phase 1\/2 clinical trial for relapsed\/refractory Ewing sarcoma, for which it has received Fast Track Designation, Orphan Drug Designation and Rare Pediatric Disease Designation from the U.S. Food and Drug Administration. Salarius is also developing seclidemstat for several cancers with high unmet medical need, with a second Phase 1\/2 clinical study in advanced solid tumors, including prostate, breast, and ovarian cancers. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also the recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pSELPm8Sxj5-bDu4pSt27JpVzG15-Hk9gW8YYrn5xHhbFKADDiCvdqX_jNGF4rVbDFvU9YiS7T8xeuKZ-RljyOuSnpcKrXrCZ2zQuybTAA8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">salariuspharma.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<br \/><\/strong>This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as \u201canticipate,\u201d \u201cpotential,\u201d \u201cprogress,\u201d \u201cdesign,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201cwill,\u201d \u201caim,\u201d \u201ccan,\u201d \u201cbelieve,\u201d \u201cplan,\u201d \u201callow,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cgoal,\u201d \u201cprovide,\u201d \u201cable to,\u201d \u201cposition,\u201d \u201cproject,\u201d \u201cdeveloping,\u201d and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements relating to the following: The status and anticipated progress and milestones of Salarius\u2019 clinical trials in advanced solid tumors and Ewing sarcoma; statements related to Salarius\u2019 developing cancer therapies for patients that need them the most, Salarius\u2019 developing seclidemstat for several cancers with high unmet medical need; Salarius\u2019 developing seclidemstat as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the sufficiency of Salarius\u2019 capital resources; the ability of, and need for, Salarius to raise additional capital to meet Salarius\u2019 business operational needs and to achieve its business objectives and strategy; Salarius\u2019 ability to project future capital needs and cash utilization and timing and accuracy thereof; the ability of Salarius to access the remaining funding available under the CPRIT grant; future clinical trial results and impact of results on Salarius; that the results of studies and clinical trials may not be predictive of future clinical trial results; the sufficiency of Salarius\u2019 intellectual property protection; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; market conditions and regulatory or contractual restrictions which may impact the ability of Salarius to raise additional capital; the possibility of unexpected expenses or other uses of Salarius\u2019 cash resources; risks related to the COVID-19 outbreak; and other risks described in Salarius\u2019 filings with the Securities and Exchange Commission, including those discussed in Salarius\u2019 quarterly report on Form 10-Q for the quarter ended September 30, 2020 and in Salarius\u2019 annual report on Form 10-K for the year ended December 31, 2019. The forward-looking statements contained in this press release speak only as of the date of this press release and are based on management\u2019s assumptions and estimates as of such date. Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.<\/p>\n<p align=\"justify\">\n        <strong>Contact<\/strong>\n      <\/p>\n<p>Tiberend Strategic Advisors, Inc.<br \/>Maureen McEnroe, CFA\/Miriam Miller (Investors)<br \/>(212)\u00a0375-2664\/ 2694\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X4AD4LsqaAVz2JVIe_BkXoRL74_nsHsMbNCMJHSnwv88nleAf4qZhOzqkWNxkz3lVaD4l46TrF-LQmmQD2fXQ1YLRPLpK4eA7LOU6E8ZHQo=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mmcenroe@tiberend.com<\/a>\/<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1_r1RF5lQFFFD5GG3Fx8NqVIYv4RFOCQO_sXIs6m5SjKuVBHI2MTdbXoQBhmPQhJAG7HstEcc8WZqcmbRQ2DSJ5LzqUbiKdwvWS3jS5r2HE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">mmiller@tiberend.com<\/a><\/p>\n<p>Johanna Bennett (Media)<br \/>(212)\u00a0375-2686\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=61MxiGgIwO8vjgwzdxqFNT-297c848O95yp6XxHS4EZMwIHTrjrKt8NHLFG36QuhFdW82nS77Tw4ixFwUp82mjYhEmi2grJIr9WN65mBe3Y=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">jbennett@tiberend.com<\/a>\u00a0<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzOTIzMSMzOTM4NDgzIzIwMTY3Nzc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/55ef1b44-7da2-4b39-bc40-93caf3cda371\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>HOUSTON, Jan. 21, 2021 (GLOBE NEWSWIRE) &#8212; Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that it has received a letter from the Nasdaq Listing Qualifications staff notifying the Company that it has regained compliance with Nasdaq&#8217;s Listing Rule 5550(a)(2) pertaining to the minimum bid price requirement for continued listing on the Nasdaq Capital Market. About\u00a0Salarius Pharmaceuticals Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius\u2019 lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options. Seclidemstat is currently in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-418585","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HOUSTON, Jan. 21, 2021 (GLOBE NEWSWIRE) &#8212; Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that it has received a letter from the Nasdaq Listing Qualifications staff notifying the Company that it has regained compliance with Nasdaq&#8217;s Listing Rule 5550(a)(2) pertaining to the minimum bid price requirement for continued listing on the Nasdaq Capital Market. About\u00a0Salarius Pharmaceuticals Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius\u2019 lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options. Seclidemstat is currently in &hellip; Continue reading &quot;Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-21T13:08:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzOTIzMSMzOTM4NDgzIzIwMTY3Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement\",\"datePublished\":\"2021-01-21T13:08:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\\\/\"},\"wordCount\":729,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzOTIzMSMzOTM4NDgzIzIwMTY3Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\\\/\",\"name\":\"Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzOTIzMSMzOTM4NDgzIzIwMTY3Nzc=\",\"datePublished\":\"2021-01-21T13:08:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzOTIzMSMzOTM4NDgzIzIwMTY3Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEzOTIzMSMzOTM4NDgzIzIwMTY3Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\/","og_locale":"en_US","og_type":"article","og_title":"Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement - Market Newsdesk","og_description":"HOUSTON, Jan. 21, 2021 (GLOBE NEWSWIRE) &#8212; Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, announced today that it has received a letter from the Nasdaq Listing Qualifications staff notifying the Company that it has regained compliance with Nasdaq&#8217;s Listing Rule 5550(a)(2) pertaining to the minimum bid price requirement for continued listing on the Nasdaq Capital Market. About\u00a0Salarius Pharmaceuticals Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius\u2019 lead candidate, seclidemstat, is being studied as a potential treatment for pediatric cancers, solid tumors and other cancers with limited treatment options. Seclidemstat is currently in &hellip; Continue reading \"Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-21T13:08:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzOTIzMSMzOTM4NDgzIzIwMTY3Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement","datePublished":"2021-01-21T13:08:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\/"},"wordCount":729,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzOTIzMSMzOTM4NDgzIzIwMTY3Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\/","name":"Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzOTIzMSMzOTM4NDgzIzIwMTY3Nzc=","datePublished":"2021-01-21T13:08:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzOTIzMSMzOTM4NDgzIzIwMTY3Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEzOTIzMSMzOTM4NDgzIzIwMTY3Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/salarius-pharmaceuticals-regains-compliance-with-nasdaq-minimum-bid-price-listing-requirement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Salarius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/418585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=418585"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/418585\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=418585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=418585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=418585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}